Tiziana life sciences announces updated clinical and pet scan findings for intranasal foralumab in two new multiple sclerosis patients

New york, jan. 08, 2024 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced positive findings have been seen in a total of six out of eight intermediate size patient population expanded access (ea) patients. these patients have shown improvements in fatigue scores measured by the modified fatigue impact scale (mfis). pet scan findings showing a reduction in microglial activation was also seen in the six patients with mfis score improvement at the three-month evaluation period. pet scan findings for two additional ea patients (10 total) are planned to be available in late january.
TLSA Ratings Summary
TLSA Quant Ranking